Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus

McNeal, Monica; Rae, Mary N.; Ward, Richard L.

doi:10.1016/s0264-410x(98)00359-4

Cited by 57 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To induce consistent clinical responses in challenged pigs, generally a higher dose of heterologous virus than of homologous virus is required, similar to findings in mice (28,35). Also, the use of outbred gnotobiotic pigs (as for humans) is likely to result in responses more variable than those seen in studies using inbred mice strains (44,45,46,47). Additionally, from a clinical standpoint, children naturally infected with rotavirus shed massive amounts of rotavirus in stools, up to 10 10 to 10 11 particles per g of stool for 3 to 7 days, equating to 10 6 particles in 0.1 g of stool (19).…”

Section: Vol 74 2000mentioning

confidence: 74%

“…There are numerous reports of protective immunity against rotavirus infection in mice induced by various routes of inoculation using different forms of rotavirus antigen (e.g., live or inactivated, homologous or heterologous rotavirus [16,28,44,45,46,51]); recombinant rotaviral proteins or VLPs [12,53,54]; and DNA plasmids [8,9,31]). To date, the protective efficacy of the inactivated or 2/6-VLP rotavirus vaccines in the adult mouse model (protection against infection) did not predict the protective efficacy against rotavirus disease in the neonatal pig model.…”

Section: Vol 74 2000mentioning

confidence: 99%

See 1 more Smart Citation

Intranasal Administration of 2/6-Rotavirus-Like Particles with MutantEscherichia coliHeat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs

Yuan

Geyer

Hodgins

et al. 2000

J Virol

View full text Add to dashboard Cite

We investigated the immunogenicity of recombinant double-layered rotavirus-like particle (2/6-VLPs) vaccines derived from simian SA11 or human (VP6) Wa and bovine RF (VP2) rotavirus strains. The 2/6-VLPs were administered to gnotobiotic pigs intranasally (i.n.) with a mutant Escherichia coli heat-labile toxin, LT-R192G (mLT) Rotaviruses are the leading cause of gastroenteritis in infants and young children worldwide (37). Rotavirus particles consist of triple-layered capsids containing a segmented double-stranded RNA genome. The rotavirus core is composed of VP2, which is the most abundant protein of the central core (15% of total virion mass) and a component of the RNA polymerase complex (26). The rotavirus major inner capsid protein is VP6, which is the most abundant structural protein of rotavirus (Ͼ50% of total virion mass) (26). VP6 is highly antigenic and contains antigenic determinants shared by all group A rotaviruses and antigenic determinants unique to the subgroup specificity. In general, most animal group A rotaviruses (including SA11) are subgroup I, whereas most human group A rotaviruses (including Wa) are subgroup II (34). The surface layer of the rotavirus capsid is composed of VP7 with VP4 spikes emanating from the outer surface (26). VP7 and VP4 independently induce virus-neutralizing (VN) antibodies (34). Diversity in VP4 and VP7 neutralizing antigenic determinants determines rotavirus P and G serotype specificity, respectively.,The viral proteins and determinants associated with protective immunity against rotavirus have not been fully delineated. Fecal or intestinal immunoglobulin A (IgA) antibodies or antibody-secreting cells (ASC) directed to rotavirus were suggested as correlates of protection in several studies of different species, including humans (15,20,28,42,64,71). Neutralizing antibodies to VP4 and VP7 were protective against rotavirus infection in mice, using monoclonal antibodies or recombinant

show abstract

Section: Vol 74 2000mentioning

confidence: 74%

Section: Vol 74 2000mentioning

confidence: 99%

Intranasal Administration of 2/6-Rotavirus-Like Particles with MutantEscherichia coliHeat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs

Yuan

Geyer

Hodgins

et al. 2000

J Virol

View full text Add to dashboard Cite

show abstract

“…Their synthetic flexibility and susceptibility towards hydrolysis produces a promising matrix for adjuvants in vaccine formulations. Among polyphosphazene, poly(di(sodium carboxylatophenoxy)phosphazene, PCPP) was demonstrated for its adjuvant activity with influenza and other retrovirus-based vaccines [27,28]. Recently, PCPP has been injected with influenza virus X31 antigen subcutaneously and strong B and T cell responses were observed [79].…”

Section: Polyphosphazenesmentioning

confidence: 99%

Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases

Shakya

Nandakumar

2013

J. R. Soc. Interface.

View full text Add to dashboard Cite

Polymers as an adjuvant are capable of enhancing the vaccine potential against various infectious diseases and also are being used to study the actual autoimmune responses using self-antigen(s) without involving any major immune deviation. Several natural polysaccharides and their derivatives originating from microbes and plants have been tested for their adjuvant potential. Similarly, numerous synthetic polymers including polyelectrolytes, polyesters, polyanhydrides, non-ionic block copolymers and external stimuli responsive polymers have demonstrated adjuvant capacity using different antigens. Adjuvant potential of these polymers mainly depends on their solubility, molecular weight, degree of branching and the conformation of polymeric backbone. These polymers have the ability not only to activate humoral but also cellular immune responses in the host. The depot effect, which involves slow release of antigen over a long duration of time, using different forms (particulate, solution and gel) of polymers, and enhances the co-stimulatory signals for optimal immune activation, is the underlying principle of their adjuvant properties. Possibly, polymers may also interact and activate various toll-like receptors and inflammasomes, thus involving several innate immune system players in the ensuing immune response. Biocompatibility, biodegradability, easy production and purification, and non-toxic properties of most of the polymers make them attractive candidates for substituting conventional adjuvants that have undesirable effects in the host.

show abstract

“…PP form noncovalent complexes when formulated with antigens and/or other adjuvants, enhancing their stability and allowing multimeric presentation. Immunization with antigens formulated with PP has been shown to induce robust immune responses against rotavirus (37), cholera virus (56), influenza virus (40,44,45), hepatitis B virus (39), and BRSV (32).…”

mentioning

confidence: 99%

Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies

Mapletoft¹,

Latimer²,

Babiuk

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Bovine respiratory syncytial virus (BRSV) infects cells of the respiratory mucosa, so it is desirable to develop a vaccination strategy that induces mucosal immunity. To achieve this, various delivery routes were compared for formalin-inactivated (FI) BRSV formulated with CpG oligodeoxynucleotide (ODN) and polyphosphazene (PP). Intranasal delivery of the FI-BRSV formulation was superior to subcutaneous delivery in terms of antibody, cell-mediated, and mucosal immune responses, as well as reduction in virus replication after BRSV challenge. Although intranasal delivery of FI-BRSV also induced higher serum and lung antibody titers and gamma interferon (IFN-␥) production in the lungs than intranasal-subcutaneous and/or subcutaneous-intranasal prime-boost strategies, no significant differences were observed in cell-mediated immune responses or virus replication in the lungs of challenged mice. Interleukin 5 (IL-5), eotaxin, and eosinophilia were enhanced after BRSV challenge in the lungs of subcutaneously immunized mice compared to unvaccinated mice, but not in the lungs of mice immunized intranasally or through combinations of the intranasal and subcutaneous routes. These results suggest that two intranasal immunizations with FI-BRSV formulated with CpG ODN and PP are effective and safe as an approach to induce systemic and mucosal responses, as well to reduce virus replication after BRSV challenge. Furthermore, intranasal-subcutaneous and subcutaneous-intranasal primeboost strategies were also safe and almost as efficacious. In addition to the implications for the development of a protective BRSV vaccine for cattle, formulation with CpG ODN and PP could also prove important in the development of a mucosal vaccine that induces protective immunity against human RSV.

show abstract

Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus

Cited by 57 publications

References 21 publications

Intranasal Administration of 2/6-Rotavirus-Like Particles with MutantEscherichia coliHeat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs

Intranasal Administration of 2/6-Rotavirus-Like Particles with MutantEscherichia coliHeat-Labile Toxin (LT-R192G) Induces Antibody-Secreting Cell Responses but Not Protective Immunity in Gnotobiotic Pigs

Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases

Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies

Contact Info

Product

Resources

About